Autolus Therapeutics, a Gaithersburg, Maryland-based cell therapy biotech with operations in the UK and US, announced on April 30, 2026 that it would cut roughly 13% of its workforce. With 752 employees as of December 31, 2025, that translates to approximately 98 positions across the company's offices, including its Gaithersburg headquarters. Autolus said the reorganization is expected to be substantially complete by the third quarter of 2026 and will deliver about $15 million in annualized cost savings starting in 2027.
The April 30 disclosure also formalized employee reductions that had begun quietly in the second half of 2025. Those earlier moves were not material enough to warrant their own announcement at the time, but the company chose to roll them into this latest restructuring update. The cuts hit all areas of the business, from research and development through commercial operations and general and administrative functions.
Cell therapy is one of the most expensive corners of biotech to operate in. Manufacturing CAR-T and other autologous treatments requires high-touch facilities, long lead times, and large clinical and commercial teams. Even companies with approved products struggle to convert that complexity into stable margins, and Autolus is one of several cell therapy developers cutting headcount in 2026 as the cash runway gets tighter.
The pattern across biotech this year has been consistent. Replimune cut 60% after a second FDA rejection of its melanoma drug. Bicycle Therapeutics cut 30% after a regulatory setback on its lead bladder cancer candidate. Gossamer Bio cut 48% after a Phase 3 failure. Autolus's cut is smaller and less dramatic, but the rationale is the same: extend the runway, prioritize the lead programs, and prove a sustainable cost base before the next financing window closes.